Skip to main content
. Author manuscript; available in PMC: 2020 Sep 2.
Published in final edited form as: Invest New Drugs. 2017 Mar 10;35(5):627–633. doi: 10.1007/s10637-017-0444-1

Table 2.

Treatment-Emergent Adverse Events Occurring in > 15% of Patients

Number (%) of patients
Total N=46

Preferred Term Any grade Grade ≤ 3
Patients with any AE 46 (100) 39 (84.8)
Fatigue 30 (65.2) 3 (6.5)
Neutropenia 26 (56.5) 20 (43.5)
Thrombocytopenia 23(50) 11 (23.9)
Nausea 22 (47.8) 0 (0)
Diarrhea 21 (45.7) 2 (4.3)
Decreased appetite 19 (41.3) 0 (0)
Hypertension 19 (41.3) 15 (32.6)
Vomiting 18 (39.1) 0 (0)
Anemia 16 (34.8) 9 (19.6)
Constipation 15 (32.6) 0 (0)
Weight decreased 9 (19.6) 0 (0)
Arthralgia 8 (17.4) 0 (0)
Back pain 8 (17.4) 0 (0)
Dyspnea 8 (17.4) 2 (4.3)
Abdominal pain 7 (15.2) 1 (2.2)
Asthenia 7 (15.2) 0 (0)
Cough 7 (15.2) 0 (0)